The University of Chicago Header Logo

Connection

David T. Rubin to Chronic Disease

This is a "connection" page, showing publications David T. Rubin has written about Chronic Disease.
Connection Strength

1.028
  1. Self-Reported Failure to Address Sexual Function in Patients With Inflammatory Bowel Disease by Gastroenterologists: Barriers and Areas for Improvement. Inflamm Bowel Dis. 2022 09 01; 28(9):1465-1468.
    View in: PubMed
    Score: 0.169
  2. International Perspectives on Management of Inflammatory Bowel Disease: Opinion Differences and Similarities Between Patients and Physicians From the IBD GAPPS Survey. Inflamm Bowel Dis. 2021 11 15; 27(12):1942-1953.
    View in: PubMed
    Score: 0.160
  3. The Impact of Intestinal Complications on Health Care Costs Among Patients With Inflammatory Bowel Disease Treated With Anti-Tumor Necrosis Factor Therapies. Inflamm Bowel Dis. 2021 07 27; 27(8):1201-1209.
    View in: PubMed
    Score: 0.156
  4. Stopping Clinical Trials in Inflammatory Bowel Disease During the COVID-19 Pandemic Is Not a Responsible Act. J Crohns Colitis. 2020 Dec 02; 14(12):1765-1768.
    View in: PubMed
    Score: 0.149
  5. Effect of adalimumab on clinical laboratory parameters in patients with Crohn's disease: results from the CHARM trial. Inflamm Bowel Dis. 2012 May; 18(5):818-25.
    View in: PubMed
    Score: 0.079
  6. Aminosalicylate therapy in the prevention of dysplasia and colorectal cancer in ulcerative colitis. Clin Gastroenterol Hepatol. 2006 Nov; 4(11):1346-50.
    View in: PubMed
    Score: 0.056
  7. Upadacitinib Induction and Maintenance Therapy Improves Abdominal Pain, Bowel Urgency, and Fatigue in Patients With Ulcerative Colitis: A Post Hoc Analysis of Phase 3 Data. Inflamm Bowel Dis. 2023 11 02; 29(11):1723-1729.
    View in: PubMed
    Score: 0.046
  8. CORE-IBD: A Multidisciplinary International Consensus Initiative to Develop a Core Outcome Set for Randomized Controlled Trials in Inflammatory Bowel Disease. Gastroenterology. 2022 10; 163(4):950-964.
    View in: PubMed
    Score: 0.042
  9. The Impact of the Social Determinants of Health on Disparities in Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2022 11; 20(11):2427-2434.
    View in: PubMed
    Score: 0.041
  10. Treatment of pouchitis, Crohn's disease, cuffitis, and other inflammatory disorders of the pouch: consensus guidelines from the International Ileal Pouch Consortium. Lancet Gastroenterol Hepatol. 2022 01; 7(1):69-95.
    View in: PubMed
    Score: 0.040
  11. Older Adult Patients Use More Aminosalicylate Monotherapy Compared With Younger Patients With Inflammatory Bowel Disease: TARGET-IBD. J Clin Gastroenterol. 2022 07 01; 56(6):529-535.
    View in: PubMed
    Score: 0.039
  12. Ustekinumab Is Effective for the Treatment of Chronic Antibiotic-Refractory Pouchitis. Dig Dis Sci. 2019 12; 64(12):3596-3601.
    View in: PubMed
    Score: 0.034
  13. miR-143 and miR-145 are downregulated in ulcerative colitis: putative regulators of inflammation and protooncogenes. Inflamm Bowel Dis. 2012 Jan; 18(1):94-100.
    View in: PubMed
    Score: 0.019
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.